Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...
Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.
In this piece, we will look at the stocks Jim Cramer recently discussed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback